Welcome to our dedicated page for Abbott Laboratories news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Laboratories stock.
Abbott Laboratories (NYSE: ABT) is a globally recognized American multinational company headquartered in Abbott Park, Illinois. Founded in 1888, Abbott has established itself as a leader in medical devices and health care. The company manufactures and markets a wide range of products, including cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment, testing kits, and branded generic drugs.
Abbott's product portfolio includes pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays along with point-of-care diagnostic equipment. Approximately 60% of Abbott’s sales are derived from markets outside the United States, underlining its global reach and influence.
Recently, Abbott introduced the PROTALITY™ brand, a high-protein nutrition shake aimed at supporting weight loss while preserving muscle mass. This innovation reflects Abbott's commitment to addressing global health challenges such as obesity and muscle health. The company also continues to make strides in medical technology with advancements like the TriClip™ system for tricuspid valve repair, and the FreeStyle Libre continuous glucose monitoring systems, which have set new standards in diabetes management.
Abbott is not only focused on innovative product development but also on strategic partnerships and sustainability. The extension of their partnership with the Real Madrid Foundation, aimed at reducing childhood malnutrition and promoting healthy habits, is a testament to their commitment to global health improvements.
Financially, Abbott has demonstrated robust performance, as evidenced by its consistent dividend payouts and its inclusion in the S&P 500 Dividend Aristocrats Index. The company reported strong Q1 2024 results with significant growth in their core business segments, further supported by successful product launches and clinical innovations.
Abbott’s mission to help people live more fully at all stages of life drives their development of life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. With a workforce of over 114,000 employees serving people in over 160 countries, Abbott continues to set benchmarks in the healthcare industry.
Abbott (NYSE: ABT) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8 a.m. Central time. Robert B. Ford, the CEO, will lead the presentation. A live webcast will be available on Abbott's Investor Relations website, with an archived version posted later that day. Abbott is recognized as a global healthcare leader, providing life-changing technologies across diagnostics, medical devices, nutritionals, and branded generic medicines. The company serves over 160 countries with a workforce of 109,000 colleagues.
Abbott (NYSE: ABT) has appointed Robert B. Ford as the new Chairman of the Board, effective immediately, following the retirement of Miles D. White after 38 years with the company. The transition is expected to bolster Abbott’s leadership in health technology, with Ford committed to advancing the company's mission amidst ongoing opportunities in healthcare. White praised Abbott's transformation during his tenure, while Ford expressed gratitude for White's mentorship. Abbott operates globally in diagnostics, medical devices, nutritionals, and branded generic medicines.
Abbott has announced a 4.4% increase in its quarterly common dividend, raising it to 47 cents per share, marking the 50th consecutive year of dividend growth. This payment will be made on Feb. 15, 2022, to shareholders on record by Jan. 14, 2022. The company also authorized a new $5 billion share repurchase program, supporting its strategy for sustainable shareholder returns and innovation. Abbott boasts a history of 392 consecutive quarterly dividends and is a member of the S&P 500 Dividend Aristocrats Index.
Abbott (NYSE: ABT) has launched Similac 360 Total Care, the first U.S. infant formula featuring a unique blend of five human milk oligosaccharides (HMOs) to support overall baby health, immune system, and brain development. This formula addresses the needs of the nearly 75% of parents using infant formula within the first six months due to various reasons. With over 20 years of research on HMOs, Abbott aims to narrow the gap between breast milk and formula, offering parents a scientifically backed alternative to nourish their babies.
Abbott (NYSE: ABT) announced positive data from the Leadless II study for its investigational Aveir leadless pacemaker, which showed an impressive 98% successful implantation rate among 200 patients. The device met primary safety and efficacy endpoints, with 96% of patients experiencing no serious adverse effects and 95.9% achieving effective pacing at six weeks post-implant. The findings were presented at the Asia Pacific Heart Rhythm Society's annual session and submitted for FDA review, signaling potential advancements in minimally invasive cardiac care.
Abbott and the American Diabetes Association have launched a community health partnership in Columbus, Ohio, targeting healthcare disparities for people of color living with diabetes. The initiative will educate and provide up to 150 Black adults with access to Abbott's FreeStyle Libre glucose monitoring technology. Black Americans face a 60% higher diabetes diagnosis rate and significant barriers to managing the disease effectively. This program aims to improve health outcomes and access to diabetes care technology.
Abbott reported strong financial results for Q3 2021, with sales reaching $10.9 billion, a 23.4% increase year-over-year. GAAP diluted EPS was $1.17, while adjusted diluted EPS grew 42.9% to $1.40. The company projects full-year diluted EPS of $3.55 to $3.65 and adjusted EPS of $5.00 to $5.10, indicating potential 38.4% growth. Significant product launches and acquisitions contributed to this growth, including FDA approvals for new medical devices and an acquisition of Walk Vascular.
On October 18, 2021, Abbott (NYSE: ABT) announced a partnership with Real Madrid to enhance children's health and nutrition worldwide. The initiative will provide nutritional science for the football club's teams and support programs run by the Real Madrid Foundation. Jason Sudeikis, the star of Ted Lasso, participated in an event at the New York Stock Exchange, promoting the partnership alongside teens from the Foundation's Social Sports School. The collaboration aims to impact thousands of children's health and support their potential.
Abbott (NYSE: ABT) has partnered with Real Madrid as its Health Sciences and Nutrition Partner for three years. This collaboration will support education, sports, and social welfare activities for at-risk children in 80 countries, alongside providing nutritional assistance to the men's and women's teams. Abbott aims to tackle malnutrition through this initiative, working with the Real Madrid Foundation to enhance children's health and well-being globally. This partnership aligns with Abbott's goal to improve the lives of over 3 billion people by 2030.
FAQ
What is the current stock price of Abbott Laboratories (ABT)?
What is the market cap of Abbott Laboratories (ABT)?
What does Abbott Laboratories specialize in?
What are some of Abbott’s recent product launches?
How much of Abbott’s sales are generated outside the United States?
What is Abbott’s PROTALITY™ brand?
How does Abbott support global health initiatives?
What is Abbott’s financial performance like?
How many employees does Abbott have?
Which continuous glucose monitoring system is Abbott known for?
What is Abbott's mission?
In how many countries does Abbott operate?
